TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05052957

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P140K-MGMT
Description: Ex Vivo Cultured P140K MGMT CD34+ Cells. The transduced cells are a biological product and production is detailed in the Cellular Therapy Lab standard operating procedures and IND 14099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: O6-benzylguanine
Description: O6BG is a low molecular-weight purine analog which selectively and irreversibly inactivates the DNA-repair enzyme, O6- alkylguanine DNA-alkyltransferase.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photon Based Radiotherapy
Description: Standard of care, photon-based radiotherapy (60Gy in 30 fractions) will be performed in both arms without concomitant TMZ between to 6 weeks post-operatively. Radiotherapy will be performed at UH-SCC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Temozolomide is not directly active but undergoes rapid non-enzymatic conversion at physiologic pHto the reactive compoundMTIC. The cytotoxicity of MTIC is thought to be primarily due to alkylationof DNA. Alkylation (methylation) occurs mainly at the O6 and N7 positions of guanine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Filgrastim is a 175 amino acid protein manufactured by recombinant DNA technology. Endogenous filgrastim is a glycoprotein produced by monocytes, fibroblasts, and endothelial cells, which regulates the production of neutrophils within the bone marrow.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: BCNU is a lipid soluble agent which has alkylating properties, plus an isocyanate metabolite which interferes with DNA and RNA synthesis.
Study: NCT05981365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxelotor
Description: Drug drug interaction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxelotor
Description: Drug drug interaction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Drug drug interaction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: Drug drug interaction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Description: Drug drug interaction
Study: NCT05972993

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-CR-04 vaccine 10μg
Description: mRNA CR-04 vaccine, 10 µg, is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-CR-04 vaccine 10μg
Description: mRNA CR-04 vaccine, 10 µg, is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-CR-04 vaccine 30μg
Description: mRNA CR-04 vaccine, 30 µg, is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-CR-04 vaccine 100μg
Description: mRNA CR-04 vaccine, 100 µg, is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-CR-04 vaccine 3μg
Description: mRNA CR-04 vaccine, 3 µg, is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.
Study: NCT05211024

Intervention type: DRUG
Intervention: Penicillin G Benzathine
Description: Participants in Aim 2 are receiving 28 days interval BPG intramuscular injection as part of standard of care
Study: NCT06573138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor, anti-PD-1 antibody plus Golidocitinib
Description: Selinexor, 40mg, qw, po; anti-PD1 antibody, 200mg, d1, i.v. (21d cycle); Golidocitinib, Dose 1, 150mg, qod, po; Dose2, 150mg, qd, po.
Study: NCT06572202

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychology Intervention
Description: The 14-session intervention program is designed to enhance various internal resiliency factors. It begins with an orientation to positive psychology and setting group guidelines. Cognitive resilience is developed through identifying personal and signature strengths, reappraising memories, and learning savoring techniques. Emotional resilience is strengthened by focusing on forgiveness, managing decision fatigue, and fostering positive communication. Spiritual resilience is cultivated through gratitude practices and exploring hope and optimism. Behavioral resilience is addressed by recognizing strengths in others and engaging in altruism. The final session integrates all these elements to promote lasting positive changes in engagement, relationships, meaning, and accomplishments. Mid-session feedback ensures the program's effectiveness and responsiveness to participants' needs.
Study: NCT05981365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Drug drug interaction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Drug drug interaction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Drug drug interaction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Drug drug interaction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Drug drug interaction
Study: NCT06572917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: Single dose of 0.1 mg/kg dose intravenous indomethacin as a slow infusion over 20 mins

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of intravenous normal saline placebo as a slow infusion over 20 mins
Study: NCT06574256

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemotherapy symptom Management Online Education
Description: Randomization was achieved and data collection began. Patients were given the Chemotherapy Symptom Management Education Booklet and were informed that they would be contacted by phone.~In the second and third stages of data collection, they were called by phone on the 7th day after receiving chemotherapy treatment. The symptoms experienced by the patient were evaluated with the N-SDS and the quality of life was evaluated with the EORTC QLQ-C30. Online nursing education videos were sent to the women in the intervention group regarding the symptoms they experienced. The practices they performed from the suggestions in the education videos and education booklets sent were recorded on the nurse follow-up form.~In the fourth stage, the practices specified in the third stage were repeated on the 7th day after the third chemotherapy course, and at this stage, the satisfaction of the women in the intervention group with the online education was evaluated.
Study: NCT06572761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of antibiotics
Description: Ceftriaxone : 1g/day parenteral clarithromycin 500 mg\*2/day orally metronidazole 500mg\*3/ day orally

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emergency cerclage
Description: Emergency cerclage

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Emergency cerclage
Description: Emergency cerclage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone
Description: Vaginal progesterone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal progesterone
Description: Vaginal progesterone
Study: NCT06573047

Intervention type: OTHER
Group type: OTHER
Intervention: kinesotape
Description: a- Kinesio-tape: cure tape (made in Korea) made from 100% gentle cotton fibre and 100% medical grade acrylic adhesive. its Hypoallergenic, water-resistant and does not limit range of motion (ROM), it is come with different colours and sizes. Kinesio Tape is safe enough for a baby's sensitive skin, and gentle enough for aging individuals, flexible enough for rehabilitation, durable enough to support working muscle, joint or ligament and strong enough for athletes at any level.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Chest physiotherapy exercises
Description: selected chest physiotherapy exercise three times per week for two weeks, each session will be about 20 minute which will include the following exercise ( huffing , coughing , percussion,and postural drainage)
Study: NCT06148597

Intervention type: PROCEDURE
Intervention: Modified thoracoabdominal nerves block through perichondrial approach (M-TAPA)
Description: application local anesthetic between internal oblique and transversus abdominis muscle at the level of 10th costal cartilage
Study: NCT04755660

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise behavior change for resistance exercise
Description: The intervention includes motivational interviews and self-efficacy theory-based exercise behavior and home-based resistance exercise intervention (by Elastic Band or non- Elastic Band ), and 3 follow-up telephone calls. The usual care group will receive exercise counseling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise behavior change for resistance exercise
Description: The intervention includes motivational interviews and self-efficacy theory-based exercise behavior and home-based resistance exercise intervention (by Elastic Band or non- Elastic Band ), and 3 follow-up telephone calls. The usual care group will receive exercise counseling.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Exercise behavior change for resistance exercise
Description: The intervention includes motivational interviews and self-efficacy theory-based exercise behavior and home-based resistance exercise intervention (by Elastic Band or non- Elastic Band ), and 3 follow-up telephone calls. The usual care group will receive exercise counseling.
Study: NCT05557279

Intervention type: DRUG
Group type: OTHER
Intervention: 500 mg NDS-446
Description: All participants will receive 500 mg NDS-446 daily for 12 weeks following a baseline assessment
Study: NCT06118086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REM-422
Description: * REM-422 is a first in class, small molecule mRNA inhibitor that reduces expression of the MYB transcription factor~* REM-422 will be administered orally once daily
Study: NCT05544877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated 5-day Gratitude Exercise and Behavioral Activation Program
Description: The 5-day intervention integrates a brief behavioral activation (BA) and a gratefulness exercise (GE) program. BA is composed of a lab-based idea generation and planning phase as well as a home-based performing phase with regard to pleasurable activities. GE is a idea generation task about aspects in life participants are grateful for about. It is performed once lab-based and daily with a home-based diary.
Study: NCT05794893

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Good Behavior Game
Description: Universal school-based intervention reinforcing prosocial behaviors and discouraging disruptive behaviors in young students.
Study: NCT06255730

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate Ganglion Block
Description: the patients in the observation group were provided with Stellate Ganglion Block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate Ganglion Block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study: NCT05212610

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfizer-BioNTech mRNA COVID-19 vaccine
Description: Participants will receive an initial or additional dose of a highly protective COVID-19 mRNA vaccine for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus in an environment where the investigators and staff are experienced in the care of patients with allergic reactions.
Study: NCT06490224

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Relevant Patient Reported Outcome Measures (PROMs)
Description: Depending on the participant's complaint: Hip disability and osteoarthritis outcome score JR (HOOS JR), Knee disability and osteoarthritis outcome score JR (KOOS JR), Quick Disabilities of the Arm, Shoulder, and Hand, Quick Disabilities of the Arm, Shoulder, and Hand (QUICKDASH), Patient Health Questionnaire 9 (PHQ-9), General Anxiety Disorder-7 (GAD7), Patient Self-Efficacy Questionnaire (PSEQ-2), Patient-Reported Outcomes Measurement Information System (PROMIS Global 10)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relevant Patient Reported Outcome Measures (PROMs)
Description: Depending on the participant's complaint: Hip disability and osteoarthritis outcome score JR (HOOS JR), Knee disability and osteoarthritis outcome score JR (KOOS JR), Quick Disabilities of the Arm, Shoulder, and Hand, Quick Disabilities of the Arm, Shoulder, and Hand (QUICKDASH), Patient Health Questionnaire 9 (PHQ-9), General Anxiety Disorder-7 (GAD7), Patient Self-Efficacy Questionnaire (PSEQ-2), Patient-Reported Outcomes Measurement Information System (PROMIS Global 10)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: My Whole Health Map
Description: Short visual map of responses to 10 questions of subjective measures.
Study: NCT05638126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-1780 table or placebo
Description: HRS-1780 table or placebo single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-1780 table or placebo
Description: HRS-1780 table or placebo single dose with food effect

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-1780 table or placebo
Description: HRS-1780 table or placebo multiple dose
Study: NCT06577818

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CC+SI (Chest compression during sustained inflation)
Description: CC+SI (Chest compression during sustained inflation)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3:1 C:V (3:1 Compression:Ventilation ratio)
Description: 3:1 C:V Group (Control group - Standard of Care): Newborns randomized to 3:1 C:V will receive a CC rate of 90/min and 30 ventilations/min as per current resuscitation guidelines. The PIP used for the 30 inflations will also be 30cmH2O) as per current resuscitation guidelines. Every 60sec, a HR assessment as per neonatal guidelines will be performed to assess if HR is \<60/min - continue CC or \>60/min - stop CC (current standard of care). 3:1 C:V will be continued until ROSC.
Study: NCT06575205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational video
Description: Participants will view a brief 3-to-5-minute educational video (VIDEO), covering information that is already printed on FDA labels for OTC NSAIDs, on their own device covering themes such as: defining OTC NSAIDs, potential harms of NSAIDs, and alternatives.
Study: NCT06344884

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early catheter removal
Description: Catheter removal the day after surgery as opposed to standard of care (3 to 4 days after surgery)
Study: NCT05544877

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrated 5-day Gratitude Exercise and Behavioral Activation Program
Description: The 5-day intervention integrates a brief behavioral activation (BA) and a gratefulness exercise (GE) program. BA is composed of a lab-based idea generation and planning phase as well as a home-based performing phase with regard to pleasurable activities. GE is a idea generation task about aspects in life participants are grateful for about. It is performed once lab-based and daily with a home-based diary.
Study: NCT04095858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efprezimod alfa
Description: IV infusion: 480 mg at Day -1, 240 mg at Day 14, 240 mg at Day 28.
Study: NCT06255730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: the patients in the observation group were provided with Stellate Ganglion Block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate Ganglion Block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study: NCT05883527

Intervention type: OTHER
Intervention: Not applicable as not an intervention - PLwD and family/carers
Description: Exploring the safeguarding process through interviews.

Intervention type: OTHER
Intervention: Not applicable as not an intervention - PLwD and family/carers
Description: Exploring the safeguarding process through interviews.

Intervention type: OTHER
Intervention: Not applicable as not an intervention - PLwD and family/carers
Description: Exploring the safeguarding process through interviews.

Intervention type: OTHER
Intervention: Not applicable as not an intervention - HCP's
Description: Exploring the safeguarding process through interviews and a focus group.
Study: NCT05090085

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3M Adper Single Bond2
Description: Two-step etch and rinse dental adhesive system

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3M Adper Single Bond2
Description: Two-step etch and rinse dental adhesive system

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Filtek Z350 XT, 3 M ESPE, St Paul, MN, USA)
Description: Composite Resin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Filtek Z350 XT, 3 M ESPE, St Paul, MN, USA)
Description: Composite Resin

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3m ESPE etch
Description: 32% phosphoric acid

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3m ESPE etch
Description: 32% phosphoric acid

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OT Primer
Description: Dimethyl Sulfoxide DMSO \[(CH3)2SO\] is a polar aprotic solvent that dissolves both polar and non-polar compounds.
Study: NCT06222398

Intervention type: DEVICE
Intervention: Exoskeleton
Description: The study will include one group of patients who are current exoskeleton users.
Study: NCT05991492

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Web-based Cognitive Behavioral Therapy for Insomnia (wCBT-I
Description: Digital insomnia treatment
Study: NCT04785378

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical mask
Description: Participants will carry out field tests one day wearing a medical mask and the other day without a mask.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Field tests
Description: Participants will perform 6 MWT and ISWT tests to determine their exercise capacity, and a 30-second sit and stand test to determine lower extremity endurance.
Study: NCT05831878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab vedotin
Description: 2.0mg/kg, iv, day1, every 2 weeks
Study: NCT06320184

Intervention type: DIAGNOSTIC_TEST
Intervention: Artificial Intelligence risk model
Description: Combining blood-based biomarkers, radiologic parameters, clinical features, and AI tools to create a robust model to predict lung cancer risk.

Intervention type: DIAGNOSTIC_TEST
Intervention: Artificial Intelligence risk model
Description: Combining blood-based biomarkers, radiologic parameters, clinical features, and AI tools to create a robust model to predict lung cancer risk.
Study: NCT05693259

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrolyzed Alkaline Reduced Water (EARW) generated from electrolyzed ionizer
Description: Patient will be allocated randomly to two groups: EARW and PW groups. For 6 weeks, patients drink water (10mL/kg body weight/day ) generated from the device installed in the house before starting intervention. Patients will be instructed to drink in empty stomach, and to drink immediately after generation of water. The total amount that the patient drank the day before will be monitored by a researcher using survey form of mobile phone everyday.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Electrolyzed Alkaline Reduced Water (EARW) generated from electrolyzed ionizer
Description: Patient will be allocated randomly to two groups: EARW and PW groups. For 6 weeks, patients drink water (10mL/kg body weight/day ) generated from the device installed in the house before starting intervention. Patients will be instructed to drink in empty stomach, and to drink immediately after generation of water. The total amount that the patient drank the day before will be monitored by a researcher using survey form of mobile phone everyday.
Study: NCT06140537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg Tab
Description: Dapagliflozin 10mg orally daily
Study: NCT04095858

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion, 100 ml at Day -1, Day 14, and Day 28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: IV, 15 mg/m\^2/dose at Day 1, then 10 mg/m2/dose at Day 3, 6, 11.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: IV, 15 mg/m\^2/dose at Day 1, then 10 mg/m2/dose at Day 3, 6, 11.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Begin on day -3. IV \[0.03 mg/kg/day\] or PO \[0.045 mg/kg/dose\] dosing is permitted

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tacrolimus
Description: Begin on day -3. IV \[0.03 mg/kg/day\] or PO \[0.045 mg/kg/dose\] dosing is permitted
Study: NCT05740930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Partition defocus myopia management spectacle lens
Description: Participants in the intervention group will receive the partition defocus myopia management spectacles lens and receive follow-up checks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spectacle lenses with aspherical lenslets
Description: Participants in the control group will receive the spectacle lenses with aspherical lenslets and receive follow-up checks.